Tracking TEGSEDI safety during pregnancy
Part of Brain & nervous system, Genetic & congenital, Women’s health & pregnancy clinical trials.
This study tracks the safety of the medicine TEGSEDI during pregnancy for women with hATTR-PN, a rare genetic nerve condition. It compares outcomes between those who took TEGSEDI while pregnant and those who did not, to better understand any risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are pregnant and have taken TEGSEDI within 25 weeks before conception or during pregnancy, OR you are pregnant and have a diagnosis of hATTR-PN but have not taken TEGSEDI.
- You are willing and able to provide informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program monitors the safety of the drug patisiran during pregnancy. If you have received patisiran around the time of pregnancy, it may help track any effects on you and your baby.
This trial tests whether the drug tafamidis can help people with a specific type of nerve damage caused by abnormal protein buildup. It aims to slow or improve symptoms in adults with this condition.
This is an observational study (no study drug) for people with transthyretin (TTR)–mediated amyloidosis, including people who carry certain gene changes before symptoms begin. It may help researchers better understand how the disease affects health over time and what to measure in future treatments.
This study uses PET/CT scans to look at the heart in people who carry a genetic change (TTR mutation) that can cause a heart condition called amyloidosis, and compares them with people who have symptoms and healthy controls. It may help doctors better understand and detect the disease earlier.
This study looks at how a heart medication (tafamidis) affects amyloid protein levels in the blood over time. It may help doctors understand how well the treatment works for people with a specific type of heart disease caused by amyloid buildup (ATTR-CM).
This trial is for people with a specific inherited form of amyloidosis caused by a change in the TTR gene. It offers a comprehensive care program to help manage this rare condition.
Hear when a new Pregnancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.